Ayala Pharmaceuticals Inc (ADXS)

[ubmmg]

Snip:

clinical activity of ADXS-503 administered alone (initially) and in combination with a checkpoint inhibitor in approximately 50 patients with NSCLC in different lines of therapy, at up to 20 centers across the U.S. Advaxis anticipates initial data from the first cohort of ADXS-503 in the first half of 2019.

They did not clarify what CPI is used.